Quetiapine Fumarate Immediate Release (IR) versus Extended Release (XR) Dose Escalation Comparison

Study identifier:D1443C00033

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Double-blind, Double-dummy, Randomized, Crossover Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (SEROQUEL®) with Quetiapine Fumarate Extended Release (SEROQUEL XR®) During Initial Dose Escalation in Healthy Volunteers

Medical condition

Healthy Volunteers

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Quetiapine Fumarate

Sex

All

Actual Enrollment

63

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 01 Jul 2008
Primary Completion Date: 01 Aug 2008
Study Completion Date: 01 Aug 2008

Study design

Allocation: Randomized
Endpoint Classification: N/A
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria